



# ReVivo Medical

## Press Release

### ReVivo Medical's Efficacy Study Published in *The Spine Journal*

July 17, 2018. ReVivo Medical, LLC announced today that *The Spine Journal* has published in its July issue, the results of its efficacy study demonstrating that load-sharing through elastic micro-motion accelerates bone formation and interbody fusion. "Our goal at ReVivo Medical is to invent and bring to market medical devices that will improve patient outcomes and reduce costs," says Gary Mittleman, president and CEO. "This recognition by the leading medical spine journal is an impressive confirmation of the efficacy of our technology."

"Anterior cervical plates are used in over 400,000 surgical procedures each year," says Dr. Darryl DiRisio, Professor of Neurosurgery and A. John Popp Chair, Spinal Surgery at Albany Medical Center. "The primary measure of success in these operations is the rapid achievement of bone fusion which thereby stabilizes the spine."

"Bone formation and patient healing can be accelerated if spinal implants provide an optimal amount of micro-motion. This is part of the uniqueness of ReVivo's flagship product" explains Eric Ledet, PhD., Chief Science Officer. "Our study unequivocally demonstrates the efficacy and advantages of our technology. We showed greater than 46% improvement in bone growth than the commonly used state of the art translationally dynamic plates and achieved a superior rate and quality of fusion. We are very proud that we have been able to apply the technical theory of bone biomechanics to an important real world application."

"The cervical plate design and the surgical methods of use are covered by our four issued patents," states Glenn Sanders, Ph.D., Chief Technology Officer. Having this patent protection is particularly important to establish our commercial presence in this \$900 million market."

The research and article were conducted and written by Eric Ledet, Ph.D., Glenn Sanders Ph.D., Darryl DiRisio, MD and Joseph Glennon, VMD. A copy of the manuscript is available on our web site [www.revivomedical.com](http://www.revivomedical.com)

**About ReVivo Medical, LLC.** Head quartered in Albany, New York, is developing elastic micro-motion implantable medical products for use by surgeons on patients with spinal pathology. The founders, Darryl DiRisio, MD. Professor of Neurosurgery and A. John Popp Chair, Spinal Surgery at the Albany Medical Center and biomedical



# ReVivo Medical

engineers Eric Ledet, PhD. and Glenn Sanders, PhD. teamed up in 2011 with the aim of developing products that improve patient health, facilitate an easier surgery process and reduce costs in this ever competitive healthcare arena. The Company expects its first commercial sales in 6 to 12 months.

## **Cautionary Statement Regarding Forward Looking Statements**

This press release contains forward-looking statements that are not purely historical regarding ReVivo Medical's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the development, cost, size, intended use and technical specifications of the medical products, the potential impact on outcomes and costs associated with spinal surgeries, and the potential profits to be made by ReVivo Medical pursuant to the successful commercialization of their product(s) and the size of market and market share of products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from ReVivo Medical's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the inability to successfully develop new products and obtain regulatory approval; a lack of acceptance in the marketplace by physicians and patients; the inability to manufacture products in commercial quantities at an acceptable cost; possible delays in the company's development programs; the inability of patients or hospitals to receive reimbursement from third-party payors; and inadequate financial and other resources.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to ReVivo Medical, and ReVivo Medical assumes no obligation to update any such forward-looking statement or reasons why results might differ.

**Contacts:** ReVivo Medical, LLC. [www.revivomedical.com](http://www.revivomedical.com)  
Gary Mittleman, President and CEO (518) 227-0743 or [gmittleman@revivomedical.com](mailto:gmittleman@revivomedical.com)  
Eric Ledet, PhD., Chief Science Officer (518) 227-0743 [eledet@revivomedical.com](mailto:eledet@revivomedical.com)